All gene expression data was deposited to the National Center for Biotechnology Information Gene Expression Omnibus public database repository (<http://www.ncbi.nlm.nih.gov/geo/>) and is accessible under GEO accession number GSE62346.

Introduction {#sec001}
============

Critically ill preterm and full-term infants in the neonatal intensive care unit (NICU) undergo inescapable stress, often for prolonged periods. These infants are commonly exposed to high doses of morphine to provide analgesia, sedation, and to treat neonatal abstinence syndrome \[[@pone.0123047.ref001]\]. The individual and combined effects of stress and morphine may affect neurodevelopment \[[@pone.0123047.ref002]\]. To evaluate these potential influences on developmental outcomes, we developed mouse and rat models of neonatal stress and morphine treatment to assess short- and long-term effects on development. The hippocampus is a logical focus because it mediates learning, it contains opioid receptors \[[@pone.0123047.ref003]\], and hippocampal mu-opioid receptor densities are altered by prenatal morphine \[[@pone.0123047.ref004]\] or adult immobilization stress \[[@pone.0123047.ref005]\].

A series of experiments identified that early stress and morphine produce lasting behavioral and hormonal effects including impairment of learning and increased sensitivity to hypoxia \[[@pone.0123047.ref006]--[@pone.0123047.ref010]\]. In addition, when we exposed neonatal mice to stress with and without morphine, we identified patterns of hippocampal mRNA expression associated with either morphine, stress, or the combination of morphine+stress. For example, neonatal stress and morphine elevated expression of mitochondrial electron transport-related gene sets, but down-regulated gene sets related to brain development and growth \[[@pone.0123047.ref011]\]. Morphine administration before and during pregnancy can cause cerebellar cortex thinning (Purkinje and internal granular layers) with Purkinje cell loss and decreased size of Purkinje cells in neonatal mice \[[@pone.0123047.ref012]\]. The mechanisms involved in regulating these morphine and stress-mediated changes in the developing brain remain unclear.

Morphine-mediated changes in hippocampal gene expression may involve regulation by miRs. miRs are single-stranded nonprotein-coding RNA transcripts that regulate gene expression by binding to the 3′ untranslated regions of mRNA transcripts to either inhibit mRNA translation or reduce mRNA stability \[[@pone.0123047.ref013]\]. More than 60% of mammalian mRNA transcripts are regulated by miRs \[[@pone.0123047.ref014]\]. Thousands of gene networks, many related to nervous system development and function, are regulated by miR activity \[[@pone.0123047.ref015]--[@pone.0123047.ref021]\]. A variety of morphine-modulated miRs are recognized with effects on addiction, brain development and immune function \[[@pone.0123047.ref022]--[@pone.0123047.ref025]\]. For example, *let-7* miRs regulate opioid tolerance by repressing translation of mu opioid receptor mRNA, *miR-154* and *miR-675* are increased in mice trained to self administer morphine \[[@pone.0123047.ref026], [@pone.0123047.ref027]\], morphine decreases *miR-133b* in immature rat hippocampal neuron cultures \[[@pone.0123047.ref028]\], and morphine increases *miR-15b* and decreases *miR-181b* in human monocyte-derived macrophages \[[@pone.0123047.ref029]\]. Since miRs regulate developmental gene expression and cellular functions, changes in miR expression secondary to morphine exposure may adversely impact neurodevelopment.

During critical care, a substantial number of premature infants are treated with morphine to reduce pain and stress and this raises concerns about the potential impact of stress and morphine on brain development \[[@pone.0123047.ref002]\]. We hypothesized that morphine may mediate changes in neonatal brain gene expression by altering miR-mediated mRNA regulation in stressed mice. If true, identifying whether neonatal morphine exposure affects miR-regulated pathways that may be deleterious to brain development is important. We describe the acute effects of neonatal morphine treatment on mRNA and miR expression in mouse hippocampus, and evaluate the miR-targeted mRNA pathways that are affected by neonatal morphine.

Materials and Methods {#sec002}
=====================

Animals {#sec003}
-------

Adult wild-type C57BL/6 mice were purchased (Harlan, San Diego, CA) and housed under a 12 h light-dark cycle with free access to food and water. Breeding was performed with two females per cage. Birth was recorded as postnatal day (P) 1. Litters were culled to n = 7 maximum per dam. Mortality and weights were monitored. All animal procedures were approved by the University of Washington's Animal Care and Use Committee.

Treatments {#sec004}
----------

Beginning on P5, male mice were assigned to one of 3 treatment conditions: untreated control (Con), morphine 2 mg/kg + stress (MS2), and morphine 5 mg/kg + stress (MS5). Untreated control animals were housed normally and exposed to minimal handling. Treated pups were exposed to stress, apnea, and morphine. To produce stress, mice were separated from the dam and isolated in cups within a veterinary warmer at 32°C (08:00 h to16:00 h). To simulate apnea, mice were exposed to 100% N~2~ for 1 min then 100% O~2~ for 5 min, twice daily (08:00 and 15:30 h). Just prior to each apnea exposure, mice received 10 μL *s*.*c*. injections of morphine. After treatments, mice were then returned to the home cage with the untreated control littermates and could nurse overnight *ad lib*. Experiments were repeated to acquire six animals per treatment condition.

Tissue collection {#sec005}
-----------------

All animals were killed on P9 by overdose with Beuthanasia-D (2.2 mL/kg, *i*.*p*.). After euthanasia, animals underwent cervical dislocation, brains were quickly removed, and bilateral hippocampi were dissected and pooled into a prelabeled tube that was immediately frozen in liquid nitrogen and then stored at -80°C until assay. RNA from the hippocampus was extracted using the Qiagen miRNeasy Kit protocol (Qiagen, Valencia, CA). RNA concentration was determined by measuring OD~260~ with a NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). RNA purity was assessed by measuring OD~260/280~ and OD~260/230~ ratios. RNA integrity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Palo Alto, CA). Only RNA samples with 28S and 18S ribosomal RNA peaks that were baseline separated, and with OD~260/280~ and OD~260/230~ ratios of 1.8--2.1 were used for further analysis.

Microarray processing and data analysis {#sec006}
---------------------------------------

RNA samples were prepared for hybridization onto Agilent mouse 8x60k mRNA microarrays (Agilent Technologies, Inc. Santa Clara, CA) using 200 ng of total RNA per sample and the manufacturer's established protocols. RNA from 5 animals of each experimental group was arrayed on 15 arrays. Hybridization and washing of these arrays was accomplished using HS 400 Pro hybridization and wash stations (Tecan Systems, Inc., San Jose, CA) and scanned using an Agilent DNA Microarray Scanner (Agilent Technologies, Inc. Santa Clara, CA) using previously established methods. Raw microarray data were preprocessed with the Agilent Feature Extraction image analysis software (Agilent) and processed using Bioconductor *Agi4x44PreProcess* package with the *normexp* option for background adjustment and *quantile normalization* for inter-array correction \[[@pone.0123047.ref030]\]. Using the normalized data, we detected differential expression using Bioconductor's limma software package, which calculates a p-value for each gene using a modified t-test in conjunction with an empirical Bayes method to moderate the standard errors of the estimated log-fold changes, and we estimated the false discovery rate using Bioconductor *p*.*adjust* \[[@pone.0123047.ref031]--[@pone.0123047.ref034]\].

Processing of the RNA samples for the Affymetrix GeneChip miR Array, which contains probe sets designated for various species including mouse, was performed according to the standard protocol recommended by the manufacturer ([www.affymetrix.com/](http://www.affymetrix.com/)) using 500 ng of total RNA per sample. RNA from 3 animals of each experimental group were used for miR expression profiling on 9 arrays. Hybridized Affymetrix arrays were scanned with an Affymetrix GeneChip 3000 fluorescent scanner. Image generation and feature extraction was performed using Affymetrix GeneChip Command Console Software. Raw GeneChip miR array data was preprocessed with Affymetrix miR QCTool software (<http://www.affymetrix.com/products_services/arrays/specific/mi_rna.affx#1_4>). The preprocessing steps include the following: probe specific signal detection calls based on a Wilcoxon Rank-Sum test of the miR probe set signals compared to the distribution of signals from GC content matched antigenomic probes, background estimation and correction, constant variance stabilization on probes, probe level quantile normalization, and finally probe summarization using median polish. miR RNA arrays included oligo spike-in controls for monitoring array quality. Arrays were required to pass manufacturer's quality control recommendations before further analysis. Only probes for *Mus musculus* were used in the subsequent analysis. miRs with significant evidence for differential expression were identified using the limma software. *P*-values were calculated with a modified *t* test ~~with~~ in conjunction with an empirical Bayes method to moderate the standard errors of the estimated Log-fold changes. *P*-values were adjusted for multiplicity with the Bioconductor package q value \[[@pone.0123047.ref035]\], which allows for selecting statistically significant miRs at a chosen estimated false discovery rate. P-values shown in text, tables and figures are unadjusted p-values unless otherwise stated. All samples and all expression values were used in the analysis of the data, that is, potential outliers were not removed from the analysis.

Quantitative TaqMan based RT-PCR analysis of protein coding mRNA {#sec007}
----------------------------------------------------------------

Quantitative PCR (qPCR) analysis was performed to validate gene expression changes for the seven specific genes (*Aqp1*, *Avp*, *Calml4*, *Cldn2*, *Defb11*, *Fign*, *Renla*) that exhibited the greatest differential expression observed in microarray analysis. Reverse transcription was performed according to the manufacturer's established protocol using total RNA and the SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). For gene expression measurements, 2 μL of cDNA were included in a PCR reaction (12 μL final volume) that also consisted of the ABI inventoried TaqMan Gene Expression Assays mix and the TaqMan Gene Expression Master Mix according to the manufacturer's protocol (Applied Biosystems, Inc., Foster City, CA, USA). Amplification and detection of PCR amplicons for *Avp* and *Cldn2* were performed with the ABI PRISM 7900 system (Applied Biosystems, Inc., Foster City, CA, USA), whereas the ROCHE LightCycler 480 was used for *Aqp1*, *Calml4*, *Defb1*, *Fign and Renla*. The following PCR reaction profile was used: 1 cycle of 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) amplification plots derived from serial dilutions of an established reference sample were used to create a linear regression formula in order to calculate expression levels. GAPDH gene expression levels were utilized as an internal control to normalize the data. This was carried out independently for the data that was generated with the ABI PRISM 7900 system as well as the ROCHE LightCycler 480. The same 15 samples, each derived from a different mouse, were used for RT-PCR analysis and mRNA expression profiling. The normalized qPCR data were compared directly using t-tests and also via conventional linear model using morphine dose as a continuous independent variable. The following TaqMan RT-PCR assays from Life Technologies (Carlsbad, CA, USA) were used to assess expression of *Retnla*, *Defb11*, *Aqp1*, *Calml4*, *Fign*, *Cldn2*, *Avp* and *GAPDH*: *Retnla* Assay ID Mm00445109_m1, *Defb11* Assay ID Mm02029641_u1, *Aqp1* Assay ID Mm00431834_m1, *Calml4* Assay ID Mm01174378_m1, *Fign* Assay ID Mm01275471_m1, *Cldn2* Assay ID Mm00516703_s1, *Avp* Assay ID Mm00437761_g1, *GAPDH* Assay ID Mm99999915_g1.

Quantitative TaqMan based RT-PCR analysis of miRs {#sec008}
-------------------------------------------------

Reverse transcription was performed using the Life Technologies TaqMan MicroRNA RT Kit following the manufacturer's established protocol for multiplex RT for TaqMan MicroRNA Assays. In addition to the manufacturer's standard reagents, 20ng of total RNA was used in conjunction with a multiplex RT primer pool (created by pooling TaqMan primers, drying down in a speed vacuum, and adjusting volume for a 62.5nM concentration for each primer). After Reverse Transcription was completed, Real-Time PCR was carried out on an ABI Prism 7900 Sequence Detection System (Life Technologies) with *U6* snRNA used as an endogenous control to normalize the miR RT-PCR data. RT-PCR analysis was performed for *miR-448*, *miR-34c*, *miR-34c\**, *miR-204*, *miR-1839-3p*, *miR-153*, *miR-1983*, *miR-214*, *miR-455*, *miR-574-3p*. In addition to the 9 samples that were used for miR array expression profiling, 4 additional biological replicates each for the 2 mg/kg and 5 mg/kg experimental groups, and 2 additional replicates for the 0 mg/kg control group were used for miR RT-PCR analysis, for a total of 19 samples. The following TaqMan RT-PCR assays from Life Technologies were used to assess expression of *mmu-miR-455*, *mmu-miR-574-3p*, *mmu-miR-448-5p*, *mmu-miR-45c-5p*, *mmu-miR-34c-3p*, *mmu-miR-204*, *mmu-miR-1839-3p*, *mmu-miR-153*, *mmu-miR-1983*, *mmu-miR-214* in mouse: 002455 (*mmu-miR-455*), 002349 (*mmu-miR-574-3p*), 464921_mat (*mmu-miR-448-5p*), 000428 (*mmu-miR-45c-5p*), 001197 (*mmu-miR-204*), 002584 (*mmu-miR-34c\*)*, 121203_mat (*mmu-miR-1839-3p*), 001191 (*mmu-miR-153*), 121204_mat (*mmu-miR-1983*), 002306 (*mmu-miR-214*) and 001973 (*U6* snRNA).

Gene Set Enrichment Analysis of mRNA array data {#sec009}
-----------------------------------------------

For Gene Set Enrichment Analysis, we used the Bioconductor package limma's *romer* function, which boosts the signal-to-noise ratio and performs a cross-correlation analysis to detect sets of genes in which the constituents show coordinated changes in expression \[[@pone.0123047.ref036]--[@pone.0123047.ref038]\]. To be stringent, only gene sets meeting the criterion of P \< 0.01 were considered, and qualifying gene sets were cross-tabulated to exclude sets that were duplicated or that were subsets of a larger qualifying gene set. We used the Broad Institute's Molecular Signatures Database (MSigDB) collection of \>10,000 gene sets divided into 7 major collections, and we chose two major collections (C2 and C5) which were curated genes (subsets Biocarta, Reactome), and the Gene Ontology (GO) gene sets (subsets: cellular component, molecular function and biological process) respectively (<http://www.broadinstitute.org/gsea/msigdb/index.jsp>).

Identification of miR targets {#sec010}
-----------------------------

The miR target feature of the Ingenuity Pathway Analysis software was used to identify miR targets (<http://www.ingenuity.com/>, Version 18030641 (Release Date: 2013-12-06)). IPA uses the TargetScan database for predicted miR-mRNA targets. TargetScan uses seed paring to predict mRNA targets. High predicted confidence is assigned either if the relationship is between a conserved or highly conserved miR as defined by TargetScan and at least one conserved site on the targeted sequence or the total context score, as defined by TargetScan, is -0.4 or less. This indicates that the miR is predicted to repress the expression of its mRNA target to 40% of the \"normal\" level. Moderate predicted confidence is assigned if the total context score, as defined by TargetScan, is -0.2 or less. This indicates that the miR is predicted to repress the expression of its mRNA target to 65% of the \"normal\" level. The miR targets presented below were all predicted with high or moderate confidence.

Public database {#sec011}
---------------

All gene expression data have been deposited to the National Center for Biotechnology Information Gene Expression Omnibus public database repository (<http://www.ncbi.nlm.nih.gov/geo/>). The data is accessible under GEO accession number GSE62346.

Results {#sec012}
=======

To assist the reader with interpretation of the data, [Fig 1](#pone.0123047.g001){ref-type="fig"} is a flow diagram illustrating the general experimental design and analysis.

![Flow diagram illustrating the experimental design and analysis.\
Neonatal mice were treated from postnatal day five (P5) to P9 as described and RNA was analyzed as shown. Abbreviation: molecular signatures database (MSigDB).](pone.0123047.g001){#pone.0123047.g001}

Single Gene Analysis {#sec013}
--------------------

Morphine produced differential expression (\>1.5 fold, p\<0.05) of neonatal mouse hippocampal genes. Overall, 150 of 21,045 probesets exhibited differential expression and [Fig 2](#pone.0123047.g002){ref-type="fig"} is a Venn diagram illustrating the comparative distribution of those effects. From these 150 probesets, 100 unique genes with functionally meaningful annotations were recognized (21 genes were up- and 79 genes were down-regulated). Select morphine-responsive mRNAs (p\<0.05) are listed in [Table 1](#pone.0123047.t001){ref-type="table"} and are sorted based on fold change. Seven of the genes most affected by morphine, as determined by microarray, were also quantified by qPCR (highlighted in [Table 1](#pone.0123047.t001){ref-type="table"}) and those data were analyzed using dose of morphine as a continuous covariate. Five of the seven genes re-quantified using qPCR exhibited corroborating changes in expression that also varied significantly as a function of morphine dose. The entire single gene analysis and a heat map are available in ([S1 Table](#pone.0123047.s002){ref-type="supplementary-material"} and [S1 Fig](#pone.0123047.s001){ref-type="supplementary-material"}).

![Venn diagram showing differential expression (\>1.5-fold, p ≤ 0.05) of mRNAs that are unique as well as those shared by the three morphine dose contrasts indicated.](pone.0123047.g002){#pone.0123047.g002}

10.1371/journal.pone.0123047.t001

###### Single Genes affected by MS5.

![](pone.0123047.t001){#pone.0123047.t001g}

  Symbol                                              Systematic Name (NM)   mRNA fold change log~2~ compared to Control   Protein                                         
  --------------------------------------------------- ---------------------- --------------------------------------------- ----------------------------------------------- -----------------------------------------
  *Defb11* [^*a*^](#t001fn004){ref-type="table-fn"}   139221                 -0.16                                         -2.11[\*\*](#t001fn003){ref-type="table-fn"}    defensin beta 11
  *Aqp1* [^*b*^](#t001fn005){ref-type="table-fn"}     007472                 0.16                                          -1.79[\*](#t001fn002){ref-type="table-fn"}      aquaporin 1
  *Calml4* [^*c*^](#t001fn006){ref-type="table-fn"}   138304                 -0.27                                         -1.71[\*\*](#t001fn003){ref-type="table-fn"}    calmodulin-like 4
  *Cldn2* [^*d*^](#t001fn007){ref-type="table-fn"}    016675                 -0.10                                         -1.52[\*\*](#t001fn003){ref-type="table-fn"}    claudin 2
  *Folr1*                                             008034                 -0.23                                         -1.48[\*\*](#t001fn003){ref-type="table-fn"}    folate receptor 1
  *Slc4a5*                                            1166067                0.06                                          -1.47[\*\*](#t001fn003){ref-type="table-fn"}    solute carrier 4, 5
  *Sulf1*                                             172294                 -0.18                                         -1.34[\*\*](#t001fn003){ref-type="table-fn"}    sulfatase 1
  *Kl*                                                013823                 -0.27                                         -1.28[\*\*](#t001fn003){ref-type="table-fn"}    klotho
  *Car14*                                             011797                 -0.12                                         -1.10[\*\*](#t001fn003){ref-type="table-fn"}    carbonic anhydrase 14
  *Msx1*                                              010835                 -0.14                                         -1.01[\*\*](#t001fn003){ref-type="table-fn"}    msh homeobox 1
  *Sln*                                               025540                 0.18                                          -0.90[\*](#t001fn002){ref-type="table-fn"}      sarcolipin
  *F5*                                                007976                 -0.10                                         -0.77 [\*\*](#t001fn003){ref-type="table-fn"}   coagulation factor V
  *Defb35*                                            139224                 -0.28 [\*](#t001fn002){ref-type="table-fn"}   -0.76 [\*\*](#t001fn003){ref-type="table-fn"}   defensin beta 35
  *Tgfbi*                                             009369                 -0.09                                         -0.73 [\*\*](#t001fn003){ref-type="table-fn"}   transforming growth factor, beta
  *Pcolce2*                                           029620                 -0.12                                         -0.72 [\*\*](#t001fn003){ref-type="table-fn"}   procollagen C proteinase enhancer 2
  *Hoxb3*                                             1079869                -0.17                                         -0.64 [\*\*](#t001fn003){ref-type="table-fn"}   homeobox B3
  *Loxl1*                                             010729                 -0.11                                         -0.63 [\*\*](#t001fn003){ref-type="table-fn"}   lysyl oxidase-like 1
  *Defb10*                                            139225                 -0.01                                         -0.60 [\*\*](#t001fn003){ref-type="table-fn"}   defensin beta 10
  *Itgax*                                             021334                 -0.44 [\*](#t001fn002){ref-type="table-fn"}   -0.60 [\*\*](#t001fn003){ref-type="table-fn"}   integrin alpha X
  *Tcea3*                                             011542                 0.07                                          -0.60 [\*\*](#t001fn003){ref-type="table-fn"}   transcription elongation factor A (SII)
  *Cdh7*                                              172853                 0.16                                          0.61[\*](#t001fn002){ref-type="table-fn"}       cadherin 7, type 2
  *Epha10*                                            177671                 0.33                                          0.63[\*](#t001fn002){ref-type="table-fn"}       Eph receptor A10
  *Zmat4*                                             177086                 0.36                                          0.67[\*](#t001fn002){ref-type="table-fn"}       zinc finger, matrin t4
  *Oprk1*                                             011011                 -0.04                                         0.81[\*](#t001fn002){ref-type="table-fn"}       opioid R, kappa1
  *Fign* [^*e*^](#t001fn008){ref-type="table-fn"}     021716                 -0.14                                         1.52[\*\*](#t001fn003){ref-type="table-fn"}     Fidgetin
  *Trh*                                               009426                 -0.20                                         1.98[\*\*](#t001fn003){ref-type="table-fn"}     thyrotropin-releasing hormone
  *Avp* [^*f*^](#t001fn009){ref-type="table-fn"}      009732                 0.30                                          2.45[\*](#t001fn002){ref-type="table-fn"}       arginine vasopressin
  *Retnla* [^*g*^](#t001fn010){ref-type="table-fn"}   020509                 0.37                                          2.58[\*\*](#t001fn003){ref-type="table-fn"}     resistin like alpha

Selected single genes exhibiting differential microarray gene expression in hippocampus taken from neonatal mice exposed to a mild stress and morphine (2 or 5 mg/kg) protocol. Superscripts (a-g) highlight seven of the genes most affected whose expression patterns were also quantified by qPCR and analyzed using morphine dose as a covariate. Genes are ordered by increasing fold change of MS5.

Array P-values: \* P ≤ 0.05

\*\* P ≤ 0.01; qPCR P-values

^*a*^ 0.01

^*b*^ 0.02

^*c*^ 0.01

^*d*^ 0.05

^*e*^ 0.58

^*f*^ 0.04

^*g*^ 0.45.

Gene Set Enrichment Analysis (GSEA) {#sec014}
-----------------------------------

Gene sets and pathways with concordant changes in expression were identified using separate Romer analyses based on the GO:C5 (cell/molecular/biological), Biocarta and Reactome gene set collections. Tables [2](#pone.0123047.t002){ref-type="table"}--[6](#pone.0123047.t006){ref-type="table"} list the gene sets that are significantly altered at p\<0.01 in mouse hippocampus following neonatal morphine exposure (MS5 *vs*. controls) and complete listings are provided in ([S2](#pone.0123047.s003){ref-type="supplementary-material"}--[S6](#pone.0123047.s007){ref-type="supplementary-material"} Table). Upregulated gene sets in the MS5 group were frequently related to cell signaling/synaptic transmission, cyclic AMP signaling, glutamate receptor activity, and regulation of lymphocyte activation. Gene sets downregulated following MS5 exposure were frequently related to transmembrane transport and cellular development. Biocarta GSEA identified effects of morphine on immunomodulation pathways including beta-arrestin and T cell signaling, death domain, nuclear factor kappa B (NF-kB), and stress-related signaling. Reactome GSEA found notable effects of morphine on neurotransmission including upregulation of GABA and opioid signaling, and downregulation of NOTCH, apoptosis, and lipid and carbohydrate metabolism.

10.1371/journal.pone.0123047.t002

###### GO:C5 MS5-upregulated mRNA pathways.

![](pone.0123047.t002){#pone.0123047.t002g}

  Gene Set Description                           P                              \# Up   \# Down
  ---------------------------------------------- ------------------------------ ------- ---------
  *Cellular Component*                           (none met criterion P\<0.01)           
  *Molecular Function*                                                                  
  3\',5\'-cAMP Phosphodiesterase Activity        0.003                          11      2
  Cyclic Nucleotide Phosphodiesterase Activity   0.004                          12      2
  N-methyltransferase Activity                   0.001                          8       5
  Oxidoreductase Activity                        0.008                          18      12
  Phosphatase Inhibitor Activity                 0.001                          10      1
  Phosphatase Regulator Activity                 0.009                          19      6
  Serotonin Receptor Activity                    0.001                          7       3
  SH2 Domain Binding                             0.005                          11      4
  Sodium Channel Activity                        0.008                          10      5
  Transcription Elongation Regulator Activity    0.009                          7       3
  *Biological Process*                                                                  
  B Cell Activation                              0.008                          11      8
  Behavior                                       0.003                          76      57
  Calcium-mediated Signaling                     0.003                          11      4
  cAMP-Mediated Signaling                        0.004                          40      23
  Cell Activation                                0.007                          38      30
  Central Nervous System Development             0.0002                         64      53
  Chromosome Organization and Biogenesis         0.003                          7       3
  Endothelial Cell Proliferation                 0.0001                         7       3
  G Protein Receptor Pathway                     0.0004                         175     142
  Hormone Secretion                              0.002                          12      4
  Leukocyte Differentiation                      0.010                          21      14
  Lymphocyte Activation                          0.010                          13      7
  Multicellular Organismal Process               0.0002                         76      62
  Muscle Contraction                             0.0001                         13      5
  Myeloid Cell Differentiation                   0.005                          11      6
  Negative Regulation of Catalytic Activity      0.003                          37      28
  Neurological System Process                    0.004                          201     152
  Positive Regulation of Cell Adhesion           0.001                          8       3
  Regulation of Homeostasis                      0.003                          8       4
  Response to Extracellular Stimulus             0.007                          18      14
  Second Messenger-mediated Signaling            0.001                          85      61

Gene sets (GO:C5) with mRNAs exhibiting upregulated expression due to neonatal morphine (MS5) exposure. Alphabetical order.

10.1371/journal.pone.0123047.t003

###### GO:C5 MS5-downregulated mRNA pathways.

![](pone.0123047.t003){#pone.0123047.t003g}

  Gene Set Description                     P        \# Up   \# Down
  ---------------------------------------- -------- ------- ---------
  *Cellular Component*                                      
  Early Endosome                           0.003    4       13
  Integrin Complex                         0.004    4       15
  Ruffle                                   0.005    8       23
  *Molecular Function*                                      
  Amino Acid Transmembrane Transport       0.004    8       20
  Beta Tubulin Binding                     0.002    1       8
  Carbohydrate Kinase Activity             0.009    3       12
  CH-CH Oxidoreductase Activity            0.001    3       18
  Collagen Binding                         0.008    3       10
  DNA Polymerase Activity                  0.006    4       14
  Identical Protein Binding                0.0001   109     182
  Metalloexopeptidase Activity             0.008    2       11
  Organic Acid Transmembrane Transport     0.003    12      31
  Peptidase Activity                       0.0001   60      101
  Protease Inhibitor Activity              0.008    10      20
  Protein Dimerization Activity            0.002    69      101
  Transition Metal Ion Binding             0.008    34      63
  Translation Initiation Factor Activity   0.0001   1       22
  Unfolded Protein Binding                 0.007    11      29
  *Biological Process*                                      
  Angiogenesis                             0.005    0       13
  Anion Transport                          0.009    7       20
  Bile Acid Metabolic Process              0.003    2       8
  Carbohydrate Response                    0.004    3       8
  Cell Adhesion                            0.008    33      50
  Cell Division                            0.005    4       16
  NF-κB Cascade                            0.007    40      67
  Nucleotide Sugar Metabolism              0.004    2       8
  Organ Morphogenesis                      0.007    50      90
  Peptide Metabolic Process                0.005    2       7
  Proteolysis                              0.001    67      111
  Tube Development                         0.001    5       13
  Vitamin Transport                        0.009    1       10

Gene sets (GO:C5) with mRNAs exhibiting downregulated expression due to neonatal morphine (MS5) exposure. Alphabetical order.

10.1371/journal.pone.0123047.t004

###### GO:C5 MS5-mixed expression mRNA pathways.

![](pone.0123047.t004){#pone.0123047.t004g}

  Gene Set Description                 P       \# Up   \# Down
  ------------------------------------ ------- ------- ---------
  *Cellular Component*                                 
  Cell Cortex Part                     0.008   4       12
  Extracellular Region                 0.008   170     225
  *Molecular Function*                                 
  Histone Acetyltransferase Activity   0.005   6       5
  Hydrolysis of Glycosyl Bonds         0.002   15      26
  Hydrolysis of Glycosyl Compounds     0.002   13      18
  *Biological Process*                                 
  Aging                                0.001   5       6
  Cell Proliferation                   0.008   52      95
  DNA Replication                      0.003   5       14
  Glutamine Family Metabolism          0.006   9       4
  Heme Biosynthetic Process            0.003   4       6
  Homeostatic Process                  0.008   85      105
  Signal Transduction                  0.001   91      121

Gene sets (GO:C5) with mRNAs exhibiting mixed up/down expression due to neonatal morphine (MS5) exposure. Alphabetical order.

10.1371/journal.pone.0123047.t005

###### Biocarta MS5-responsive Gene sets.

![](pone.0123047.t005){#pone.0123047.t005g}

  Pathway (Biocarta)   P        \# Up   \# Down
  -------------------- -------- ------- ---------
  *UP*                                  
  β-Arrestin Src       0.0001   13      1
  CDK5                 0.0022   8       2
  CSK                  0.0027   14      5
  ERK                  0.0001   17      10
  GLEEVEC              0.0065   15      7
  HER2                 0.0018   16      4
  IGF1R                0.0029   13      8
  MAL                  0.0015   12      5
  NO2-dep IL12         0.0044   14      3
  *DOWN*                                
  ACE2                 0.0023   2       9
  AHSP                 0.0015   2       8
  ARF                  0.0015   4       12
  CARM1                0.0027   7       5
  MTA3                 0.0005   4       13
  PTC1                 0.0002   4       7
  TGFB                 0.0046   11      8
  VITCB                0.0081   3       8
  *MIXED*                               
  AMI                  0.0023   3       17
  DEATH                0.0015   9       21
  NF-κB                0.0057   4       19
  RB                   0.0003   1       11
  SODD                 0.0002   1       9

Gene sets (Biocarta) with mRNAs affected by neonatal morphine (MS5). Alphabetical order.

10.1371/journal.pone.0123047.t006

###### Reactome MS5-responsive Gene sets.

![](pone.0123047.t006){#pone.0123047.t006g}

  Pathway (Reactome)                    P        \# Up   \# Down
  ------------------------------------- -------- ------- ---------
  *UP*                                                   
  Aquaporin Mediated Transport          0.004    31      17
  Botulinum Neurotoxicity               0.002    12      3
  Circadian Clock                       0.003    30      20
  FGFR Signaling                        0.001    26      15
  GABA Receptor Activation              0.006    37      15
  Gastrin-CREB Signaling                0.008    108     83
  Glucagon Regulation of Insulin        0.002    29      12
  G-Protein Signaling                   0.004    249     195
  Interaction: L1 and Ankyrins          0.003    11      2
  Interleukin 2 Signaling               0.001    23      16
  Interleukin 3 Signaling               0.005    24      17
  Netrin1 Signaling                     0.007    6       3
  Neuronal System                       0.004    177     91
  Nitric Oxide Signaling                0.004    15      10
  Opioid Signalling                     0.003    49      26
  Phosphorylation of CD3 and TCR Zeta   0.007    8       1
  Potassium Channels                    0.004    60      37
  *DOWN*                                                 
  AKT1-mediated Events                  0.001    7       21
  Apoptosis Extrinsic Pathway           0.0002   0       11
  Calcium-mediated Platelet Response    0.007    26      49
  Caspase-mediated Protein Cleavage     0.004    3       8
  Chaperonin-mediated Biosynthesis      0.0001   4       22
  Fatty Acid Metabolism                 0.004    60      103
  Integrin Cell Surface Interactions    0.009    23      54
  Lipid Digestion and Transport         0.0003   9       33
  Metabolism of Carbohydrates           0.007    78      144
  Metabolism of Porphyrins              0.003    3       10
  Notch Receptor Cleavage               0.002    4       7
  Transmembrane Transport               0.01     87      146
  *MIXED*                                                
  DCC-mediated Attractive Signaling     0.003    7       6
  Extracellular Matrix Organization     0.006    24      58
  Meiotic Recombination                 0.009    13      40
  Methionine and cysteine Metabolism    0.007    7       17
  PDGF Signaling                        0.005    51      63
  Pre-Notch Expression                  0.003    15      25

Gene sets (Reactome) with mRNAs affected by neonatal morphine (MS5). Alphabetical order.

To combine the GSEA data from the three gene set collections, an ensemble analysis was performed by defining 9 categories of biological functions and assigning each gene set pathway identified in Tables [2](#pone.0123047.t002){ref-type="table"}--[6](#pone.0123047.t006){ref-type="table"} to a category, then the categorized data points were counted and divided by the total to create proportions. The resulting data in [Fig 3](#pone.0123047.g003){ref-type="fig"} illustrate that morphine's effects on hippocampal gene expression predominantly affected processes related to cell cycle, membrane biology, signaling, metabolism and cell death.

![Categorized Gene Set Enrichment Analysis (GSEA) data to contrast the effects of morphine detected using three separate gene set collections.\
Individual GSEA data points from Tables [2](#pone.0123047.t002){ref-type="table"}--[6](#pone.0123047.t006){ref-type="table"} were assigned to basic biological function categories and the counts for each category were divided by the total for each gene set collection (Reactome, dark gray; GO:C5, light gray; Biocarta, white). This illustrates the relative agreement between gene set collections used to detect differential gene expression after neonatal morphine treatment.](pone.0123047.g003){#pone.0123047.g003}

miR microarrays {#sec015}
---------------

To investigate whether effects of neonatal morphine on hippocampal mRNA expression in stressed mice are secondary to effects on miR expression, morphine-responsive miRs were identified. miR array profiling identified ten specific miRs that were altered (\>1.5 fold, p \< 0.05) by morphine (*miR-204*, *miR-448*, *miR-455*, *miR-574*, *miR-34c*, *miR-34c\**, *miR-1839*, *miR-153*, *miR-1983* and *miR-214*) and RT-PCR analysis was performed for those ten miRs. The first four in that list were validated by quantitative RT-PCR. [Fig 4](#pone.0123047.g004){ref-type="fig"} illustrates the dose-dependent effects of morphine on array expression (panel A) and RT-PCR expression (panel B) of *miR-204-5p*, *miR-448-5p*, *miR-455-3p*, and *miR-574-3p*. Three of those four (*not miR-574-3p*) validated miRs had mRNA targets that were also differentially expressed and [Table 7](#pone.0123047.t007){ref-type="table"} presents the morphine-responsive miRs along with their corresponding mRNA targets. These data suggest that neonatal morphine may affect both mRNA and associated miR expression in mouse hippocampus.

![Hippocampal miR expression in stressed neonatal mice was down-regulated by morphine treatment.\
Data are mean (+SEM) microarray expression (panel A) and RT-PCR expression (panel B) values presented as fold-change (log~2~) compared to untreated control mice. Values from mice receiving either 2 mg/kg morphine (unfilled bars) or 5 mg/kg morphine (filled bars) are shown. Expression values that differ significantly from control (0) are indicated as \* or \*\* = *P* ≤ 0.05 or 0.01, respectively.](pone.0123047.g004){#pone.0123047.g004}

10.1371/journal.pone.0123047.t007

###### Hippocampal miR and miR-targeted mRNA expression was altered in neonatal mice exposed to stress plus morphine (MS5) compared to control.

![](pone.0123047.t007){#pone.0123047.t007g}

  miR        Fold change log2   *P* ~miR~   Targeted mRNA                                             Fold change log2   *P* ~mRNA~                                                        mRNA product
  ---------- ------------------ ----------- --------------------------------------------------------- ------------------ ----------------------------------------------------------------- -------------------------------------------------------------
  *204-5p*   -1.222             0.049       *Ap1s2*                                                   -0.764             0.002                                                             adaptor complex 1 σ2 [^a^](#t007fn002){ref-type="table-fn"}
  *Syt6*     0.97               0.047       synaptotagmin VI [^a^](#t007fn002){ref-type="table-fn"}                                                                                        
  *448-5p*                                  *Acox2*                                                   -0.927             0.011                                                             acyl-CoA oxidase 2 [^b^](#t007fn003){ref-type="table-fn"}
                                *Kl*        -1.108                                                    0.006              klotho [^b^](#t007fn003){ref-type="table-fn"}                     
  -1.589     0.024              *Otx2*      -1.257                                                    0.031              orthodenticle homeobox 2 [^c^](#t007fn004){ref-type="table-fn"}   
                                *Prdm16*    -0.601                                                    0.023              PR domain containing 16 [^c^](#t007fn004){ref-type="table-fn"}    
                                *Sema3A*    0.599                                                     0.043              semaphorin domain 3A [^d^](#t007fn005){ref-type="table-fn"}       
  *455-5p*                                  *Ap1s2*                                                   -0.764             0.002                                                             adaptor complex 1 σ2 [^a^](#t007fn002){ref-type="table-fn"}
  -0.695     0.004              *Pdzd2*     0.596                                                     0.049              PDZ domain 2 [^e^](#t007fn006){ref-type="table-fn"}               
                                *Prg4*      0.798                                                     0.014              proteoglycan 4 [^f^](#t007fn007){ref-type="table-fn"}             

All targets are either high or moderate predicted in IPA. protein categories

^a^ transporter protein

^b^ enzyme

^c^ transcription regulator

^d^ immunoglobulin

^e^ neurotransmission

^f^ proteoglyclan. Alphabetical order.

Discussion {#sec016}
==========

Neonatal morphine exposure produced a variety of changes in mouse hippocampal gene expression. Moreover, neonatal morphine produced dose-dependent suppression of four specific miR sequences. Three of these four miRs targeted nine morphine-responsive mRNA genes. These data support the hypothesis that some morphine-induced changes in brain gene expression involve modulation of miR-mediated mRNA regulation. Although this study is a descriptive microarray analysis, these data provide a foundation for future specific hypothesis testing about possible side effects of morphine exposure during development.

The current data also raise concerns about possible deleterious effects of neonatal morphine exposure because more than 100 single genes and gene set pathways were affected. The ensemble analysis in [Fig 3](#pone.0123047.g003){ref-type="fig"} identified that neonatal morphine exposure predominantly affected cell cycle-, membrane-, signaling-, and metabolism-related functions. In a developing brain, those functions are essential for proper proliferation, differentiation and migration and, therefore, morphine's modulation or disruption of those processes could be very detrimental. This concern is validated by the fact that morphine inhibits adult neurogenesis and alters neuronal phenotypes in the rat hippocampus \[[@pone.0123047.ref039], [@pone.0123047.ref040]\].

Clinically, morphine may be prescribed to sedate infants so as to alleviate pain and stress during intensive care. Stress and morphine treatment affect hippocampal gene expression in rodents \[[@pone.0123047.ref011]\]. To understand effects of neonatal stress on brain development, we previously examined differential hippocampal mouse gene expression to compare multiple levels of neonatal stress (mild *vs*. severe) combined with 2 mg/kg morphine cotreatment \[[@pone.0123047.ref011]\]. As a follow-up, the current experiment compared multiple doses of neonatal morphine (2 *vs*. 5 mg/kg) given to severely stressed mice. In both experiments, differential single gene expression in morphine-treated mice was detected for *aquaporin*, *claudin*, *cadherin*, *and arginine vasopressin*, but in the current mice given 5 mg/kg morphine, the magnitude of the effects were either enhanced or profoundly reversed. This interaction agrees with findings from the prior experiment in which morphine treatment did *not* simply attenuate effects of neonatal stress on gene expression but, instead, additional effects were evident when morphine and stress were combined. Collectively, it is now apparent that neonatal morphine exposure produces dose-dependent changes in hippocampal gene expression when administered to treat stress.

Morphine can suppress the immune response in animals and humans \[[@pone.0123047.ref041]--[@pone.0123047.ref046]\]. Consistent with this immune inhibition, we found that morphine greatly suppressed β-defensin 11 (*Defb11)* mRNA levels, a factor known to mediate innate/adaptive immune and inflammatory responses. Given that hyperglycemia occurs during neonatal stress \[[@pone.0123047.ref047]\], and that hyperglycemia-induced neurodegeneration is also associated with *β*-defensin suppression \[[@pone.0123047.ref048]\], we speculate that neonatal morphine-induced *β*-defensin suppression could increase a neonatal animal's susceptibility to neurodegenerative injury, particularly under conditions of stress. The immunoregulatory effects of morphine may involve gene pathways, such as the morphine-mediated enhancement of ERK phosphorylation and inhibition of NF-κB signaling seen in activated human T cells \[[@pone.0123047.ref049]\]. Consistent with this morphine-mediated pathway regulation, in our MS5 mice, the ERK pathway was upregulated (see [Table 5](#pone.0123047.t005){ref-type="table"}) and the NF-κB gene pathway was downregulated (see Tables [3](#pone.0123047.t003){ref-type="table"} and [5](#pone.0123047.t005){ref-type="table"}) in the hippocampus.

Stimulatory immune-related effects of chronic morphine include increasing circulating T-regulatory and T-helper (Th) 17 cells \[[@pone.0123047.ref050]\], promoting GATA 3 and T-bet transcription factor expression to increase IL-4, IL-5 and Th2 effector cells \[[@pone.0123047.ref042]\] and increasing IL-12 production in mouse and human cells \[[@pone.0123047.ref043], [@pone.0123047.ref051]\]. Congruent with these effects, we found that neonatal morphine stimulated Th, T-cytotoxic, beta-arrestin, IL-5, and IL-12-related pathways ([Table 5](#pone.0123047.t005){ref-type="table"}, Biocarta), and also increased the lymphocyte activation pathway ([Table 6](#pone.0123047.t006){ref-type="table"}, Reactome). Recognizing that the neonatal immune response is normally limited to Th2 activity,\[[@pone.0123047.ref052]\] the artificial elevation of these factors in neonatal brain could be deleterious if it promoted brain inflammation. In fact, an elevated immune response in neonatal brain is suspect in early white matter injury \[[@pone.0123047.ref053]\].

The most novel feature of this study is that it included an analysis of miRs. We hypothesize that effects of morphine on miR expression could have lasting neuroepigenetic consequences. During early human brain development, changes in the temporal or spatial patterns of miR expression could result in epigenetic modifications that effectively alter differentiation. Throughout early human brain development, there is activity in miR-sensitive gene sets related to autism, schizophrenia, bipolar disorder and depression \[[@pone.0123047.ref054]\]. Thus there is a strong rationale for testing the hypothesis that neonatal morphine exposure may trigger permanent miR-mediated epigenetic changes, and this hypothesis provides a mechanism for understanding possible neonatal origins of childhood or adult neurologic diseases.

In our neonatal mice, three miRs, *miR-448-5p*, *mir-204-5p*, and *miR-455-5p*, which targeted 9 of the 63 experimentally determined differentially expressed mRNAs, exhibited decreased expression in MS5-treated hippocampus. The first miR, *miR-448-5p*, was matched to 5 of the morphine-responsive mRNAs (*Sema3a*, *Prdm16*, *Acox2*, *Kl*, *Otx2*) whose products are related to neurodevelopment and inflammation. For example, semaphorin 3A (*Sema3a*), was up-regulated and is associated with axonal branching \[[@pone.0123047.ref055]\]. Orthodenticle homeobox 2 (*Otx2*), Klotho (*Kl*), acyl-CoA oxidase 2 branched chain (*Acox2*), and PR domain-containing 16 (*Prdm16*) were all down-regulated. The homeobox Otx2 plays a significant role in brain development and function of mesencephalic dopaminergic neurons \[[@pone.0123047.ref056]--[@pone.0123047.ref058]\]. Moreover, Klotho is a novel β-glucoronidase transmembrane enzyme that is highly expressed in both choroid plexus and hippocampus where it produces anti-inflammatory \[[@pone.0123047.ref059], [@pone.0123047.ref060]\] and antioxidative effects, and also controls calcium and phosphate homeostasis \[[@pone.0123047.ref061]\]. In fact, Klotho-deficient mice demonstrate hippocampal neuronal degeneration and decreased cortical Purkinje cell body density \[[@pone.0123047.ref062]\]. The *Acox2* gene encodes for the branched-chain acyl-CoA oxidase protein, and deficiency of this enzyme results in the accumulation of branched fatty acids and may lead to Zellweger syndrome, severe mental retardation, and death in children \[[@pone.0123047.ref063]\]. In mice, the transcription factor Prdm16 is required for neural stem cell survival, cell cycle regulation, and self-renewal, which occurs partially by promoting Hepatocyte Growth Factor expression and regulating ROS levels \[[@pone.0123047.ref064]\].

The sequence *mir-204-5p* targeted 2 mRNA genes (*Syt6* and *Ap1s2*) and expression of the synaptotagmin (*Syt6*) was increased while adaptor-related protein complex 1, sigma 2 subunit (*Ap1s2*) was decreased. Synaptotagmins are abundant, evolutionarily conserved integral membrane proteins that mediate calcium-dependent exocytosis and neurotransmitter release \[[@pone.0123047.ref065], [@pone.0123047.ref066]\]. *Ap1s2* encodes the σ-2 subunit of the early transcription factor *Ap1* (*c-Jun*) \[[@pone.0123047.ref067]\] and the product Jun N-terminal kinase is associated with synaptic protein trafficking \[[@pone.0123047.ref068], [@pone.0123047.ref069]\]. Mutation of *AP1S2* protein is associated with X-linked Dandy--Walker malformation with intellectual disability, basal ganglia disease and seizures (Pettigrew syndrome) \[[@pone.0123047.ref067]\].

The miR *mir-455-5p* was associated with 3 altered mRNAs (*Prg4*, *Pdzd2*, *and Ap1s2*). The *miR-455-5p* was decreased and both *Prg4* and *Pdzd2* were correspondingly increased as expected based on classical miR-mRNA regulation. However, despite the suppression of both *mir-204-5p* and *miR-455-5p*, *Ap1s2* was still decreased. It is difficult to know whether the patterns of expression reflect a response to morphine, or a response to changes in expression of the other morphine-responsive factors. Given that Ap1/Jnk is associated with hippocampal apoptosis \[[@pone.0123047.ref070], [@pone.0123047.ref071]\], the decrease may be a welcome outcome. The *Prg4* gene encodes a proteoglycan that is increased in mice following experimental middle cerebral artery occlusion \[[@pone.0123047.ref072]\]. The *Pdz2* gene product regulates expression of Nav1.8 cytokine-modulated tetrodotoxin-resistant sodium channels \[[@pone.0123047.ref073], [@pone.0123047.ref074]\].

There are limitations to descriptive microarray studies that should be mentioned. First, the current databases relating mRNA genes and miR sequences may be refined in the future. Regarding interspecies conservation, the relationships between mRNA/miR in humans may be different than in mice \[[@pone.0123047.ref075]\]. Microarray effects on expression are descriptive and do not indicate whether post-transcriptional regulatory mechanisms are involved. We presume that the principal effects of morphine identified were due to direct action of morphine on hippocampal opioid receptors, but we cannot exclude the possible indirect involvement of non-hippocampal loci. We identified miR and mRNA that were altered in hippocampal tissue, but we did not identify the specific cell types expressing these molecules. Additionally, varying levels of stress, the timing of stress and morphine exposure, the concentration, dosage, and duration (acute vs chronic) of morphine, and sex-specific differences may influence hippocampal miR:mRNA interactions. We also cannot comment on the influence of stress and morphine on miR expression in other regions of the brain that may affect neurodevelopment.

Conclusion {#sec017}
==========

Repeated neonatal morphine exposure altered gene expression in the hippocampus of stressed mice, affecting pathways involved in cell cycle, membrane function, signaling, metabolism, cell death, and immune regulation. Morphine also induced a dose-dependent down-regulation of *miR-448-5p*, *mir-204-5p*, and *miR-455-5p* expression with corresponding changes in their mRNA targets involved in neurodevelopment, neurotransmission, and inflammation. If morphine--mediated neuroepigenetic effects are permanent and affect long-term hippocampal function, this would suggest one potential mechanism occurring in the neonatal period that may lead to future neurodevelopmental impairment. A better understanding of the effects of morphine on mRNA and miR expression may lead to novel pharmacological approaches to provide sedation without deleteriously altering neurodevelopmental outcomes.
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###### A heat map illustrating single gene differential mRNA expression in neonatal mouse hippocampal tissue.
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###### Romer Cellular Component gene set analysis comparing 5 mg/kg morphine (trt5) to control (trt0).
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###### Romer Biological Process gene set analysis comparing 5 mg/kg morphine (trt5) to control (trt0).
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###### Romer Molecular Function gene set analysis comparing 5 mg/kg morphine (trt5) to control (trt0).
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###### Biocarta gene set analysis comparing 5 mg/kg morphine (trt5) to control (trt0).
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###### Reactome gene set analysis comparing 5 mg/kg morphine (trt5) to control (trt0).
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